



Proteomics International

LABORATORIES LTD

ASX Release
18 February 2019

ASX code: PIQ

Upcoming release from voluntary escrow

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), wishes to advise, in accordance with ASX Listing Rule 3.10A, that 3,868,305 fully paid ordinary shares (Escrowed Shares) are due to be released from voluntary escrow on 5 March 2019.

As announced on 5 March 2018, Proteomics International issued the Escrowed Shares to acquire 10% of the fully diluted issued share capital of CPR Pharma Services Pty Ltd (CPR). In October 2018, the company received \$928,399 for its shareholding in CPR after receiving a notice that an offer to purchase all shares of CPR had been accepted by CPR's major shareholder.

A voluntary escrow period of 12 months applied to the Escrowed Shares. The Escrowed Shares are quoted securities and therefore the company will not apply for quotation thereof.

ENDS

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. Proteomics International's business model centres on the commercialisation of the company's world-leading predictive test for diabetic kidney disease, PromarkerD. The company offsets the cash burn from R&D and product development through provision of specialist analytical services across the globe, whilst using its proprietary Promarker™ technology platform to create a pipeline of novel diagnostic tests.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Susan Fitzpatrick-Napier
[Public Relations & Media Contact]
Digital Mantra Group
T: +61 2 8218 2144 or +1 415-951-3228
E: team@dmgpr.com

Dirk van Dissel
[Corporate Advisor & Investor Relations]
Adelaide Equity Partners
T: +61 8 8232 8800
E: dvandissel@adelaideequity.com.au

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com